Although, the TGFβ pathway is being evaluated as a therapeutic target in gastric cancer [28,29], the complex roles of TGFβ in tumor progression might make it difficult to select the patients that will benefit from an anti-TGFβ therapy. The gene discussed is TGFB1; the disease is neoplasm.